METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.

◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.

◆ To complement the organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.

◆ To help company to succeed in a competitive market, and
Abstract

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion.

At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.

Interventional cardiovascular devices in China include cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices, etc., among which cardiovascular stent is predominant.
Cardiovascular stent: In 2013, the Chinese cardiovascular stent market equaled RMB11.2 billion, 78.8% of which was occupied by domestic drug-eluting stents. That same year, 686,000 units of cardiovascular stent were consumed in China, up 11.7% year on year, and drug-eluting stents accounted for 99.5%, indicating that the drug-eluting stent is gradually becoming an important device for interventional cardiovascular therapy.

In addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop biodegradable stents, which are expected to be available on the market in 2017. Thanks to its excellent performance, biodegradable stents are likely to replace drug-eluting stents gradually in the future, thus becoming the main variety in domestic coronary stent market.

Balloon catheter: In 2013, China’s demand for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which were PTCA balloon catheters for dilatation. With rapid development of local PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW Medical, domestic PTCA balloon catheters increased its market share from 20% in 2009 to 40% in 2013.

Affected by the implementation of “Regulations on the Centralized Procurement of High-value Medical Consumables”, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017.

China Interventional Cardiovascular Device Industry Report, 2014-2017 focuses on the following:
- Status quo of China interventional cardiovascular device industry, including overview, market demand, import & export, competitive landscape and entry barriers;
- Development environment of China interventional cardiovascular device industry, embracing macro environment, policy climate and upstream & downstream sectors;
- Status quo, competitive landscape, etc. of China interventional cardiovascular device market segments, covering coronary stent, balloon catheter, catheter, guidewire, sheath group and auxiliary devices;
- Operation, interventional cardiovascular device business, etc. of 6 foreign and 12 Chinese interventional cardiovascular device companies.
### 1. Overview of Interventional Cardiovascular Device Industry

1.1 Definition
1.2 Classification and Application of Products
1.3 Industry Chain

### 2. Status Quo of China Interventional Cardiovascular Device Industry

2.1 Overview
2.2 Market Demand
2.3 Import & Export
2.4 Competitive Landscape
2.5 Entry Barriers
2.5.1 Technology
2.5.2 Talent
2.5.3 Patent
2.5.4 Policy
2.5.5 Market Channel

### 3. Development Environment of China Interventional Cardiovascular Device Industry

3.1 Macro Environment
3.2 Policy Climate
3.2.1 Regulatory Policies
3.2.2 Industrial Policies
3.3 Upstream & Downstream Sectors
3.3.1 Upstream
3.3.2 Downstream

### 4. Market Segments of China Interventional Cardiovascular Device Industry

4.1 Coronary Stent
4.1.1 Market Profile
4.1.2 Drug-Eluting Stent
4.1.3 Bioabsorbable Stent
4.2 Balloon Catheter
4.2.1 Market Profile
4.2.2 Supply & Demand
4.3 Catheter
4.4 Guidewire
4.5 Sheath Group and Auxiliary Devices

### 5. Foreign Companies in China

5.1 Johnson & Johnson
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 Interventional Cardiovascular Device Business
5.1.6 Development in China
5.2 Medtronic
5.2.1 Profile
5.2.2 Operation
5.3 Boston Scientific
5.3.1 Profile
5.3.2 Operation
5.3.3 Interventional Cardiovascular Device Business
5.3.4 Development in China
5.4 Abbott Laboratories
5.4.1 Profile
5.4.2 Operation
5.4.3 Interventional Cardiovascular Device Business
5.4.4 Development in China
5.5 B. Braun
5.5.1 Profile
5.5.2 Operation
5.5.3 Interventional Cardiovascular Device Business
5.5.4 Development in China
5.6 Terumo
5.6.1 Profile
5.6.2 Operation
5.6.3 Interventional Cardiovascular Device Business
5.6.4 Development in China
6. Major Domestic Companies
6.1 MicroPort
6.1.1 Profile
6.1.2 Operation
6.1.3 Revenue Structure
6.1.4 Interventional Cardiovascular Device Business
6.1.5 R&D and Investment
6.1.6 Forecast and Outlook
6.2 Lepu Medical
6.2.1 Profile
6.2.2 Operation
6.2.3 Revenue Structure
6.2.4 Gross Margin
6.2.5 Interventional Cardiovascular Device Business
6.2.6 R&D and Investment
6.2.7 Forecast and Outlook
6.3 Lifetech Scientific
6.3.1 Profile
6.3.2 Operation
6.3.3 Revenue Structure
6.3.4 Interventional Cardiovascular Device Business
6.3.5 R&D and Investment
6.3.6 Forecast and Outlook
6.4 JW Medical
6.4.1 Profile
6.4.2 Interventional Cardiovascular Device Business
6.5 Dalian Yinyi
6.5.1 Profile
6.5.2 Interventional Cardiovascular Device Business
6.6 Neich Medical (Shenzhen)
6.6.1 Profile
6.6.2 Interventional Cardiovascular Device Business
6.7 SCW Medicath
6.7.1 Profile
6.7.2 Interventional Cardiovascular Device Business
6.8 Demax Medical
6.8.1 Profile
6.8.2 Interventional Cardiovascular Device Business
6.9 Starway Medical
6.9.1 Profile
6.9.2 Interventional Cardiovascular Device Business
6.10 Synexmed
6.10.1 Profile
6.10.2 Interventional Cardiovascular Device Business
6.11 Sino Medical
6.11.1 Profile
6.12 AmsinoMed Medical Device
6.12.1 Profile

7. Forecast and Outlook
7.1 Industry
7.2 Market Segments
7.2.1 Coronary Stent
7.2.2 Balloon Catheter
• Types and Functions of Interventional Cardiovascular Device
• Types and Features of Cardiovascular Stent
• Interventional Cardiovascular Device Industry Chain in China
• Total Industrial Output Value and YoY Growth of China Medical Device Industry, 2005-2013
• Revenue and YoY Growth of China Medical Device Industry, 2005-2013
• Market Size and YoY Growth of China Interventional Cardiovascular Device Industry, 2009-2013
• Number of Patients with Cardiovascular Disease in China, 2013
• Death Rate Percentage of Major Diseases in Rural Area, 2012
• Death Rate Percentage of Major Diseases in Urban Area, 2012
• Changes in Mortality Rate of Coronary Heart Disease in Urban and Rural Areas of China, 2002-2011
• Number of PCI Cases and Growth Rate in China, 2011-2013
• Coronary Stent Implantation and Usage Percentage of Drug-eluting Stent in China, 2011-2013
• Import Share and Import Prices of Main Interventional Medical Devices in China, 2008
• China’s Intravascular Stent Imports and Exports by Top 10 Countries, 2013
• Market Structure of China Interventional Cardiovascular Device Industry, 2013
• Number of Congenital Heart Disease Patients Receiving Interventional Therapy in China, 2012-2013
• Business Models of China Interventional Cardiovascular Device Industry
• China’s GDP and YoY Growth, 1985-2013
• Main Policies Concerning Interventional Cardiovascular Device in China, 2006-2013
• Number of Medical Institutions and Sickbeds in China, 2012-2013
• Number of Hospitals in China (by Grade), 2010-Jun. 2014
• Medical Service Quantity of Health Care Facilities in China, 2012-2013
• Usage of Sickbeds in China’s Medical Institutions, 2012-2013
• Health Costs and % of GDP in China, 1980-2013
• Per Capita Health Costs and YoY Growth Rate in China, 2006-2013
• Number of People 65 and Over and % of Total Population in China, 2004-2013
• Ratio between Per Capita Income of Urban and Rural Households in China, 1980-2013
• Medical Insurance Coverage and Expenditure in China
• Proportion of Medical Insurance-covered Payment for Interventional Operation in Beijing, Shanghai and Guangzhou, 2011
• Market Share of Main Coronary Stent System Brands in China (by Consumption), 2013
• Implantation of Coronary Stent in China, 2011-2013
• China’s Coronary Stent Market Size and YoY Growth, 2012-2017E
• Comparison of Relevant Data about PCI in China, 2011-2013
• List of Main Domestic Drug-eluting Stent Products, 2013
• Market Share of Imported and Domestic PTCA Balloon Catheter Products, 2013
• China’s Interventional Cardiovascular Balloon Catheter Market Size, 2012-2017E
• China’s Demand for PTCA Balloon Catheter, 2011-2013
• China’s Interventional Cardiovascular Catheter Market Size, 2012-2017E
• China’s Interventional Cardiovascular Guide Wire Market Size, 2012-2017E
• China’s Interventional Cardiovascular Sheath Group and Auxiliary Device Market Size, 2012-2017E
• Total Revenue and Net Income of Johnson & Johnson, 2009-2014
• Total Revenue Breakdown of Johnson & Johnson (by Product), 2009-2014
• Total Revenue Structure of Johnson & Johnson (by Product), 2009-2014
• Gross Margin of Johnson & Johnson, 2009-2014
• Johnson & Johnson’s Revenue from Cardiovascular Business and YoY Growth, 2009-2013
• Johnson & Johnson’s Companies in China and Their Main Products
• Revenue and Net Income of Medtronic, FY2009-FY2013
• Revenue Breakdown of Medtronic (by Product), FY2009-FY2013
• Revenue Structure of Medtronic (by Product), FY2009-FY2013
Selected Charts

- Medtronic’s Revenue from Coronary Artery Products and % of Total Revenue, FY2009-FY2013
- Revenue, Net Income and Gross Margin of Boston Scientific, 2009-2013
- Revenue Breakdown of Boston Scientific (by Division), 2009-2013
- Revenue Breakdown of Boston Scientific (by Region), 2009-2013
- Boston Scientific’s Revenue from Cardiovascular Division and YoY Growth, 2009-2013
- Revenue, Net Income and Gross Margin of Abbott, 2009-2013
- Revenue Breakdown of Abbott (by Product), 2009-2013
- Revenue Structure of Abbott (by Product), 2009-2013
- Revenue from Cardiovascular Products and % of Total Revenue, 2009-2013
- Revenue, Net Income and Gross Margin of B. Braun, 2009-2013
- Revenue Breakdown of B. Braun (by Division), 2009-2013
- Revenue Breakdown of B. Braun (by Region), 2009-2013
- Revenue and YoY Growth of B. Braun's Aesculap Division, 2009-2013
- Revenue and Net Income of Terumo, FY2010-FY2013
- Revenue of Terumo by Business, FY2010-FY2013
- Revenue of Terumo by Region, FY2010-FY2013
- R&D Cost and Proportion in Revenue of Terumo, FY2010-FY2013
- Revenue from Cardiovascular Business and Revenue Share of Terumo, FY2010-FY2013
- PTCA Balloon Dilatation Catheter Output and YoY Growth of Terumo, FY2009-FY2013
- Angiographic Guidewire Output and YoY Growth of Terumo, FY2009-FY2013
- PTCA Guidewire Output and YoY Growth of Terumo, FY2009-FY2013
- China Branches and Their Business of Terumo
- Terumo’s Layout in China
- Revenue, Net Income and Gross Margin of MicroPort, 2009-2013
- Revenue Breakdown of MicroPort (by Product), 2011-2013
Selected Charts

- Revenue Structure of MicroPort (by Product), 2011-2013
- Revenue Breakdown of MicroPort (by Region), 2009-2013
- Revenue Structure of MicroPort (by Region), 2009-2013
- MicroPort’s Revenue from Interventional Cardiovascular Products and % of Total Revenue, 2011-2013
- MicroPort's Advantages in Heart Drug-eluting Stent Field
- R&D Costs and % of Total Revenue of MicroPort, 2009-2013
- Revenue and Net Income of MicroPort, 2012-2017E
- Distribution of Lepu Medical’s Subsidiaries
- Revenue, Net Income and Gross Margin of Lepu Medical, 2009-2013
- Revenue Breakdown of Lepu Medical (by Product), 2009-2013
- Revenue Breakdown of Lepu Medical (by Region), 2009-2013
- Gross Margin of Lepu Medical (by Product), 2009-2013
- R&D Costs and % of Total Revenue of Lepu Medical, 2010-2013
- Lepu Medical’s Projects with Raised Funds and Progress
- Revenue and Net Income of Lepu Medical, 2012-2017E
- Revenue, Net Income and Gross Margin of Lifetech Scientific, 2009-2013
- Revenue Breakdown of Lifetech Scientific (by Business), 2009-2013
- Revenue Structure of Lifetech Scientific (by Business), 2009-2013
- Lifetech Scientific’s Revenue from Congenital Heart Disease Business, YoY Growth and % of Total Revenue, 2009-2013
- Lifetech Scientific’s Revenue from Peripheral Vascular Disease Business, YoY Growth and % of Total Revenue, 2009-2013
- R&D Costs, YoY Growth and % of Total Revenue of Lifetech Scientific, 2010-2013
- Balloon Compliance of JW Medical’s EXCEL Drug-eluting Stent Delivery System
- Features of Dalian Yinyi’s Balloon Dilatation Catheters
- Technical Parameters of COMBO Dual Therapy Stent
• SCW Medicath’s PTCA Balloon Dilatation Catheters
• Features and Advantages of SCW Medicath’s PTCA Balloon Dilatation Catheters
• Technical Parameters of SCW Medicath’s PTCA Balloon Dilatation Catheters
• Technical Parameters of Demax Medical’s Gusta? PTCA Balloon Dilatation Catheters
• Technical Parameters of Demax Medical’s Gusta? PTCA Non-compliance Balloon Dilatation Catheters
• Main Technical Parameters of Synexmed’s Advancer? PTCA Balloon Catheter
• Main Technical Parameters of Synexmed’s Advancer Plus? PTCA/CTO Balloon Catheter
• Main Technical Parameters of Synexmed’s Advancer Hp? High Pressure Balloon Catheter
• Technical Parameters of Synexmed’s RUNNER? Coronary Stent
• Technical Parameters of Synexmed’s CHALLENGER? Coronary Stent
• Technical Parameters of Synexmed’s RAPA? Rapamycin Drug-eluting Coronary Stent
• Technical Parameters of Sino Medical’s BuMA? Drug-eluting Stent
• Technical Parameters of Sino Medical’s SUN Coronary Stent
• Diagram for Balloon Passing External Diameter of Sino Medical’s Sleek PTCA Rapid Exchange Dilatation Balloon Catheter
• Market Size and YoY Growth of China Interventional Cardiovascular Device Industry, 2012-2017E
You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/82601561

Party A:
Name:
Address:
Contact Person: Tel
E-mail: Fax

Party B:
Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)
Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Contact Person: Liao Yan Phone: 86-10-82600828
E-mail: report@researchinchina.com Fax: 86-10-82601570

Bank details:
Beneficial Name: Beijing Waterwood Technologies Co., Ltd
Bank Name: Bank of Communications, Beijing Branch
Bank Address: NO.1 Jinkiyuan Shijicheng, Landianchang, Haidian District, Beijing
Bank Account No #: 110060668012015061217
Routing No #: 332906
Bank SWIFT Code: COMMCNSHBJG

<table>
<thead>
<tr>
<th>Title</th>
<th>Format</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDF (Single user license)</td>
<td>…………..2,200 USD</td>
<td></td>
</tr>
<tr>
<td>Hard copy</td>
<td>………………….</td>
<td>2,400 USD</td>
</tr>
<tr>
<td>PDF (Enterprisewide license)</td>
<td>………….. 3,500 USD</td>
<td></td>
</tr>
</tbody>
</table>

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.
About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- Multi-users market reports
- Database-RICDB
- Custom Research
- Company Search

RICDB (http://www.researchinchina.com/data/database.html), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at:

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com